Paper Details

  1. Home
  2. Paper Details

Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine.

Author: , AllenC, BussoneG, HernandezJ F, PascualJ, PatelK, VrijensF

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Rizatriptan, a selective 5-HT(1B/1D) receptor agonist, was preferred by patients for the treatment of migraine compared to sumatriptan, offering faster headache relief, fewer side effects, and improved function.
Paper Details　
Original Abstract of the Article :
Rizatriptan (MAXALT, a registered trademark of Merck & Co. Inc.) is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine. This randomized, open-label, crossover outpatient study assessed the preference of 481 patients for ri...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1159/000052143

データ提供：米国国立医学図書館（NLM）

Comparing the Preference for Rizatriptan and Sumatriptan in Migraine Treatment

This study delves into the realm of [migraine treatment], comparing the preference for [rizatriptan] and [sumatriptan]. It's like exploring two different paths in the desert of migraine relief, seeking the most effective and well-tolerated route. The study involved 481 patients with migraine who were asked to compare their preference for [rizatriptan] and [sumatriptan]. The results revealed that significantly more patients preferred rizatriptan over sumatriptan, citing faster relief of headache pain as the primary reason. Rizatriptan was also found to be superior in terms of headache relief at 2 hours, pain-free status, and overall satisfaction.

Rizatriptan Offers Faster and More Effective Relief

The study indicates that rizatriptan may provide a faster and more effective solution for migraine relief. It's like discovering a shortcut through the desert, leading to a quicker and more comfortable oasis of pain relief. This finding could be significant for individuals seeking rapid relief from migraine symptoms and improved overall migraine management.

Finding the Oasis of Migraine Relief

This research highlights the importance of personalized treatment approaches for migraine. It's like choosing the right path in a vast desert, where different options may lead to different outcomes. Considering factors such as the speed of relief, pain-free status, and overall satisfaction, individuals can work with their healthcare providers to find the most suitable migraine treatment option.

Dr.Camel's Conclusion

This study offers valuable insights into the comparative effectiveness of rizatriptan and sumatriptan for migraine treatment. While both medications were effective, rizatriptan demonstrated superiority in terms of speed of relief and overall patient preference, suggesting a potential advantage for individuals seeking rapid and effective migraine management.
Date :
  1. Date Completed 2001-07-26
  2. Date Revised 2017-11-01
Further Info :

Pubmed ID

11385269

DOI: Digital Object Identifier

10.1159/000052143

Related Literature

Article Analysis
・Side Effects of rizatriptan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.